Interesting ...
AZ to showcase AZD0466 on 9 June 2023 at the European Hematology Association (EHA) 2023 Hybrid Congress
https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-showcases-scientific-advances-across-rare-and-malignant-haematological-conditions-at-eha-2023.html
- Preliminary ongoing Phase I/II safety and tolerability results of AZD0466, a Bcl-2/Bcl-xl inhibitor, will show it is tolerated as a monotherapy for patients with relapsed or refractory acute leukaemia.
AZD0466
Marconi, G
Safety and tolerability of AZD0466 as monotherapy for patients with advanced hematological malignancies - Preliminary results from an ongoing Phase I/II trial
Abstract # P537
Poster Presentation
9 June 2023
Astrazeneca-showcases-scientific-advances
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.44M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 12.5¢ | 10.5¢ | $132.0K | 1.162M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 535926 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 11.0¢ | 12.5¢ | 10.5¢ | 991112 | ||
| Last updated 15.53pm 03/05/2024 ? | |||||
| SPL (ASX) Chart |